Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
November 05, 2020 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data...
October 29, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
October 20, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia

WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S....
October 08, 2020 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN) Selecta’s IgA nephropathy program builds upon...
September 30, 2020 16:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

All data consistent with stronger performance of SEL-212 versus pegloticase Numerically higher response rate for SEL-212 versus pegloticase during primary endpoint of months 3 and 6 combined;...
September 24, 2020 16:17 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 23, 2020 07:00 ET | Source: Selecta Biosciences, Inc.

First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the...
September 08, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 01, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...